Globus Medical, Inc. (GMED)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 10/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 7.55% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- GMED or AXGN: Which Is the Better Value Stock Right Now?
- Is Spine Tech Unveiling Altering The Investment Case For Globus Medical Stock?
- Is Globus Medical (GMED) Cheap On Its Spine Platform Reveal?
- What Does Globus Medical (GMED) Mean For Spine Care After Its NASS 2026 Reveal?
- Globus Medical (GMED) Stock Looks Discounted Against Its Earnings Outlook
- Globus Medical to Showcase SCRIPT™ Patient-Specific Implants and New XLIF™ Prone Procedural Solution at NASS 2026
- OPKO Health to Sell Select BioReference Assets to Labcorp for $722M
- Reasons to Add STE Stock to Your Portfolio Right Now
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Globus Medical, Inc..
Full GMED Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.